Administrative and Coordinating Core
行政协调核心
基本信息
- 批准号:10601388
- 负责人:
- 金额:$ 20.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-18 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY – ADMINISTRATIVE AND COORDINATING CORE (ACC)
The overarching goal of the Administrative and Coordinating Core (ACC) is to provide effective leadership to
optimize the successful accomplishment of the scientific aims of the Cervical Cancer Prevention
Partnership (C2P2) Center in Peru and the Dominican Republic. The management team for the ACC includes
three investigators: a Peru-based investigator, Dr. Robinson Cabello, MPI, and two Seattle-based
investigators, Dr. Duerr (MPI and Co-Chair Trial 1) and Dr. Madeleine (Contact MPI, Co-Investigator Trials 2
and 3). Together they will provide scientific direction, enhance productivity, liaise with the NCI, and monitor
safety, quality, recruitment, and progress toward each of the Aims of the Clinical Trials and service Cores. The
Aims of the ACC are as follows: Aim 1 of the ACC is to organize the C2P2 Center by distributing responsibility
and accountability throughout the C2P2 Center. The ACC will implement the Triple C (Communication,
Cooperation and Coordination) model of project management. This organizational approach will be grounded
in meeting regional needs and in respect for working with LAC partners who will lead and sustain the cutting-
edge changes we develop together through integrated and interdisciplinary team science. Aim 2 is to facilitate
communication and scheduling at all levels of the partnership. The ACC will foster high-level and bi-
directional coordination and cooperation directly with unit leaders (Clinical Trial Co-Chairs and service Core
Leaders) across the C2P2 Center (i.e., Core teams, Clinical Trial teams, institutions), and with external
advisors (i.e., External Scientific Advisory Group and the cross-cutting Partnership Center Coordinating
Committee). Aim 3 of the ACC is to lead all trial monitoring and regulatory coordination activities with the
assistance of the Data Coordinating Core. The first priority of the ACC is patient safety at both trial sties. Aim 4
of the ACC will provide training and dissemination of findings. The ACC will administratively support the
Clinical Trial Co-Chairs through cross-institutional training as needed to refine laboratory assay quality control,
data management skills training, and streamlined organizational infrastructure building that will enhance the
success of the matrixed partnership. All trial findings will be disseminated through published papers and
presentations in the region and at international meetings of policy and guideline makers who will be able to use
our trial findings to accelerate progress toward elimination of cervical cancer through prevention. The ACC will
provide leadership to accomplish the overall scientific goal of the C2P2 Center to improve the quality and
efficiency of cervical cancer prevention in the region.
项目摘要-行政和协调核心(行政协调会)
行政和协调核心(行政协调会)的首要目标是提供有效的领导,
优化宫颈癌预防科学目标的成功实现
秘鲁和多米尼加共和国的合作伙伴关系(C2 P2)中心。ACC的管理团队包括
三名研究人员:一名秘鲁的研究人员,罗宾逊卡贝洛博士,MPI,和两名西雅图的
研究者,Duerr博士(MPI和联合主席试验1)和Madeleine博士(联系MPI,联合研究者试验2
和3)。他们将共同提供科学指导,提高生产力,与NCI联络,并监测
安全性、质量、招募以及临床试验和服务核心目标的进展。的
ACC的目标如下:ACC的目标1是通过分配责任来组织C2 P2中心
C2 P2中心的责任和义务。ACC将实施3C(沟通,
合作与协调)模式的项目管理。这种组织方法将立足于
在满足区域需求方面,以及在与拉丁美洲和加勒比合作伙伴合作方面,
我们通过综合和跨学科的团队科学共同开发的边缘变化。目标2:促进
在伙伴关系的各个层面进行沟通和安排。行政协调会将促进高级别和双-
直接与单位领导(临床试验联席主席和服务核心)进行定向协调和合作
领导者)跨C2 P2中心(即,核心团队、临床试验团队、研究机构)以及外部
顾问(即,外部科学咨询小组和跨领域伙伴关系协调中心
委员会)。ACC的目标3是领导所有试验监测和监管协调活动,
数据协调核心的支持。ACC的首要任务是两个试验中心的患者安全性。目标4
行政协调会将提供培训和传播调查结果。行政协调会将在行政上支持
临床试验联合主席通过跨机构培训(如需要)完善实验室分析质量控制,
数据管理技能培训,以及简化的组织基础设施建设,
矩阵式合作关系的成功所有试验结果将通过发表的论文和
在本区域和国际会议上向能够利用
我们的试验结果将加速通过预防消除宫颈癌的进展。ACC将
领导实现C2 P2中心的总体科学目标,提高质量和
提高该地区预防宫颈癌的效率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARGARET M MADELEINE其他文献
MARGARET M MADELEINE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARGARET M MADELEINE', 18)}}的其他基金
Therapeutic use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA Trial
HPV L1 疫苗在肛门生殖器肿瘤中的治疗用途:VIVA 试验
- 批准号:
9220396 - 财政年份:2017
- 资助金额:
$ 20.96万 - 项目类别: